An activated protein C-dependent thrombin generation assay predicts chemotherapyassociated venous thromboembolism in cancer patients

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 931-932

  Ferroni, Patrizia ^a   Martini, Francesca ^a   Portarena, Ilaria ^b   Grenga, Italia ^b   Riondino, Silvia ^a   la Farina, Francesca ^a   Laudisi, Anastasia ^b   Roselli, Mario ^a,b   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROPYRIMIDINE DERIVATIVE; HORMONE; PLATINUM COMPLEX; TAXANE DERIVATIVE; THROMBIN;

ADULT; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLOR ULTRASOUND FLOWMETRY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HUMAN; LETTER; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBIN TIME; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION TESTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN C; SENSITIVITY AND SPECIFICITY; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 79955787524     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-11-0757     Document Type: Letter

References (12)

1. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104: 1049-1054.
2. Ferroni P, Formica V, Roselli M, et al. Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Curr Vasc Pharmacol 2010; 8: 102-113.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
4. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-4926.
5. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
6. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism. The Vienna Prediction Model. Circulation 2010; 121: 1630-1636.
7. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
8. Sousou T, Khorana AA. New insights into cancerassociated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-320.
9. Douma RA, van Sluis GL, Kamphuisen PW, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010; 104: 831-836.
10. Tripodi A, Legnani C, Lemma L, et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2010; 30: 215-219.
11. Toulon P, Smirnov M, Triscott M, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 2009; 124: 137-143.
12. Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115: 5637-5650.